H.C. Wainwright raised the firm’s price target on Brainsway (BWAY) to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for Neurolief’s Proliv RX system, a class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- Brainsway price target raised to $30 from $23 at Northland
- BrainsWay Wins Draft Highmark Coverage for Accelerated Deep TMS Depression Protocol
- Brainsway announces draft coverage policy from Highmark for Deep TMS
- BrainsWay Highlights FDA Approval of Neurolief’s At-Home Proliv Rx Device for Treatment-Resistant Depression
- Brainsway announces U.S. FDA granted PMA for Neurolief’s ProlivRx system